{"entity": "publication", "iuid": "7d6479590a2f404896c516cacf3321ec", "timestamp": "2026-09-29T17:03:29.560Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7d6479590a2f404896c516cacf3321ec.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7d6479590a2f404896c516cacf3321ec"}}, "title": "Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.", "authors": [{"family": "Palma", "given": "Marzia", "initials": "M", "orcid": "0000-0003-4287-3179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fc1dd22fd3ca4eb3823866960fd240d2.json"}}, {"family": "Krstic", "given": "Aleksandra", "initials": "A"}, {"family": "Pe\u00f1a Perez", "given": "Lucia", "initials": "L"}, {"family": "Bergl\u00f6f", "given": "Anna", "initials": "A"}, {"family": "Meinke", "given": "Stephan", "initials": "S"}, {"family": "Wang", "given": "Qing", "initials": "Q"}, {"family": "Blomberg", "given": "K Emelie M", "initials": "KEM"}, {"family": "Kamali-Moghaddam", "given": "Masood", "initials": "M"}, {"family": "Shen", "given": "Qiujin", "initials": "Q"}, {"family": "Jaremko", "given": "Georg", "initials": "G"}, {"family": "Lundin", "given": "Jeanette", "initials": "J"}, {"family": "De Paepe", "given": "Ayla", "initials": "A"}, {"family": "H\u00f6glund", "given": "Petter", "initials": "P"}, {"family": "Kimby", "given": "Eva", "initials": "E"}, {"family": "\u00d6sterborg", "given": "Anders", "initials": "A"}, {"family": "M\u00e5nsson", "given": "Robert", "initials": "R"}, {"family": "Smith", "given": "C I Edvard", "initials": "CIE"}], "type": "journal article", "published": "2018-10-00", "journal": {"title": "Br. J. Haematol.", "issn": "1365-2141", "volume": "183", "issue": "2", "pages": "212-224", "issn-l": "0007-1048"}, "abstract": "In chronic lymphocytic leukaemia (CLL) patients, treatment with the Bruton tyrosine kinase inhibitor ibrutinib induces a rapid shift of tumour cells from lymph nodes (LN) to peripheral blood (PB). Here, we characterized in depth the dynamics of ibrutinib-induced inflammatory, transcriptional and cellular changes in different compartments immediately after treatment initiation in seven relapsed/refractory CLL patients. Serial PB and LN samples were taken before start and during the first 29 days of treatment. Changes in plasma inflammation-related biomarkers, CLL cell RNA expression, B-cell activation and migration markers expression, and PB mononuclear cell populations were assessed. A significant reduction of 10 plasma inflammation markers, the majority of which were chemokines and not CLL-derived, was observed within hours, and was paralleled by very early increase of CD19+ circulating cells. At the RNA level, significant and continuous changes in transcription factors and signalling molecules linked to B-cell receptor signalling and CLL biology was observed in both PB and LN CLL cells already after 2 days of treatment. In conclusion, ibrutinib seems to instantly shut off an ongoing inflammatory response and interfere with diverse sensitive pathways in the LN.", "doi": "10.1111/bjh.15516", "pmid": "30125946", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T11:49:13.814Z", "modified": "2026-09-23T11:49:13.830Z"}